Matches in SemOpenAlex for { <https://semopenalex.org/work/W2537120422> ?p ?o ?g. }
Showing items 1 to 70 of
70
with 100 items per page.
- W2537120422 endingPage "2042" @default.
- W2537120422 startingPage "2042" @default.
- W2537120422 abstract "2042 Background: Combination of paclitaxel (PTX) with pegylated liposomal doxorubicin (PLD) is an interesting opportunity for recurrent head/neck cancer treatment. Their pharmacokinetic (PK) behavior could be dependent not only on PTX excipient (polyethoxylated castor oil) interference, but also on different iv administration interval between the two drugs. The study endpoint was to evaluate any possible administration interval-dependent PK interaction, when PLD infusion start is delayed from 0 to 24 h after PTX infusion end. Methods: 24 patients affected by recurrent cisplatin pre-treated squamous cellhead/neck cancer were enrolled, receiving PTX 80 mg/m 2 q 1w and PLD 12.5 mg/m 2 q 2w for 6w/2w rest. Administration interval was 0 h at d1 (PTX-PLD 0) and 24 h at d15 (PTX-PLD 24). Blood sampling was performed at d1–15, PTX and PLD blood levels were analyzed by high performance liquid chromatography techniques, while PK parameters by non-compartmental analysis. Results: PTX PK parameters had large statistically significant differences (median/IQR, PTX-PLD 0 vs. PTX-PLD 24, Mann-Whitney test): Cmax 261/219–531 vs. 407/250–1473 ng/ml p=0.142, AUC 869/688–1331 vs. 3361/969–7853 ng*h/ml p=0.013, Kel 0.39/0.26–0.57 vs. 0.11/0.02–0.26 h⁁ −1 p=0.001, Cl 153/89–198 vs. 41/17–138 l/h p=0.013. Similarly, PLD Cmax and AUC were higher in PTX-PLD 24 (Cmax 5.1/3.3–8.1 vs. 6.8/5.3–7.8 mg/l p=0.043, AUC 341/104–1472 vs. 603/106–1006 mg*h/l p=1.000). The overall response rate was 37.5%, including 1 CR (4%); median response duration was 5.5 months (range, 2–16), median overall survival 10 months (range, 2–25+). Conclusions: This exploratory study, having a favourable palliative role in heavily pre-treated patients, showed that PTX PK profile is unexpectedly affected by a different administration interval. In PTX-PLD 0, PTX AUC is fourfold reduced, with a similar increase in Cl, totally due to Kel alteration: therefore, patients could be underexposed to PTX. PLD PK behavior confirmed previous studies results, in which PTX modified PLD disposition, prolonging the duration of its elimination phase and increasing total body exposure to PLD. No significant financial relationships to disclose." @default.
- W2537120422 created "2016-10-28" @default.
- W2537120422 creator A5001339286 @default.
- W2537120422 creator A5004472086 @default.
- W2537120422 creator A5029036674 @default.
- W2537120422 creator A5056206202 @default.
- W2537120422 creator A5057001950 @default.
- W2537120422 creator A5062491559 @default.
- W2537120422 creator A5066038668 @default.
- W2537120422 creator A5071628074 @default.
- W2537120422 date "2006-06-20" @default.
- W2537120422 modified "2023-10-14" @default.
- W2537120422 title "Paclitaxel and pegylated liposomal doxorubicin in recurrent head/neck cancer: An unexpected administration interval-dependent pharmacokinetic interaction" @default.
- W2537120422 doi "https://doi.org/10.1200/jco.2006.24.18_suppl.2042" @default.
- W2537120422 hasPublicationYear "2006" @default.
- W2537120422 type Work @default.
- W2537120422 sameAs 2537120422 @default.
- W2537120422 citedByCount "0" @default.
- W2537120422 crossrefType "journal-article" @default.
- W2537120422 hasAuthorship W2537120422A5001339286 @default.
- W2537120422 hasAuthorship W2537120422A5004472086 @default.
- W2537120422 hasAuthorship W2537120422A5029036674 @default.
- W2537120422 hasAuthorship W2537120422A5056206202 @default.
- W2537120422 hasAuthorship W2537120422A5057001950 @default.
- W2537120422 hasAuthorship W2537120422A5062491559 @default.
- W2537120422 hasAuthorship W2537120422A5066038668 @default.
- W2537120422 hasAuthorship W2537120422A5071628074 @default.
- W2537120422 hasConcept C112705442 @default.
- W2537120422 hasConcept C126322002 @default.
- W2537120422 hasConcept C126894567 @default.
- W2537120422 hasConcept C22979827 @default.
- W2537120422 hasConcept C2776694085 @default.
- W2537120422 hasConcept C2777292972 @default.
- W2537120422 hasConcept C2778239845 @default.
- W2537120422 hasConcept C71924100 @default.
- W2537120422 hasConcept C76318530 @default.
- W2537120422 hasConcept C90924648 @default.
- W2537120422 hasConcept C98274493 @default.
- W2537120422 hasConceptScore W2537120422C112705442 @default.
- W2537120422 hasConceptScore W2537120422C126322002 @default.
- W2537120422 hasConceptScore W2537120422C126894567 @default.
- W2537120422 hasConceptScore W2537120422C22979827 @default.
- W2537120422 hasConceptScore W2537120422C2776694085 @default.
- W2537120422 hasConceptScore W2537120422C2777292972 @default.
- W2537120422 hasConceptScore W2537120422C2778239845 @default.
- W2537120422 hasConceptScore W2537120422C71924100 @default.
- W2537120422 hasConceptScore W2537120422C76318530 @default.
- W2537120422 hasConceptScore W2537120422C90924648 @default.
- W2537120422 hasConceptScore W2537120422C98274493 @default.
- W2537120422 hasIssue "18_suppl" @default.
- W2537120422 hasLocation W25371204221 @default.
- W2537120422 hasOpenAccess W2537120422 @default.
- W2537120422 hasPrimaryLocation W25371204221 @default.
- W2537120422 hasRelatedWork W1539293547 @default.
- W2537120422 hasRelatedWork W1836451026 @default.
- W2537120422 hasRelatedWork W1967512152 @default.
- W2537120422 hasRelatedWork W1976273181 @default.
- W2537120422 hasRelatedWork W1982777678 @default.
- W2537120422 hasRelatedWork W2125585793 @default.
- W2537120422 hasRelatedWork W2145658083 @default.
- W2537120422 hasRelatedWork W2350403668 @default.
- W2537120422 hasRelatedWork W2552418679 @default.
- W2537120422 hasRelatedWork W4283074304 @default.
- W2537120422 hasVolume "24" @default.
- W2537120422 isParatext "false" @default.
- W2537120422 isRetracted "false" @default.
- W2537120422 magId "2537120422" @default.
- W2537120422 workType "article" @default.